Patients with metastatic disease or with locoregional recurrence inaccessible to salvage local therapy are treated with systemic therapies according to their general health status (performance status), comorbidities, previous treatment, PD-L1 tumor expression, tumor evolutivity and symptoms [69]. The gene discussed is CD274; the disease is metastatic neoplasm.